HCM - Hutchmed begins 1b/2 study of HMPL-453 combo to treat solid tumors in China

Hutchmed (China) said the first patient was dosed a phase 1b/2 study in China of HMPL-453 in combination with chemotherapy or anti-PD-1 therapy toripalimab to treat patients with specific advanced or metastatic solid tumors. The first stage of the study is a dose escalation phase to determine the recommended phase 2 dose of of HMPL-453 in combination with chemotherapy (gemcitabine and cisplatin) or toripalimab. The second stage is a dose expansion phase in solid tumor patients with either gastric cancer, intrahepatic cholangiocarcinoma, or urothelial carcinoma, harboring specific FGFR gene alterations. The company said a phase 2 study of HMPL-453 monotherapy is also underway in patients with advanced intrahepatic cholangiocarcinoma in China. HCM +0.85% premarket to $26.0

For further details see:

Hutchmed begins 1b/2 study of HMPL-453 combo to treat solid tumors in China